Navigation Links
New technique uses 'simulated' human heart to screen drugs
Date:7/21/2014

A Coventry University scientist has developed a pioneering new way using samples of beating heart tissue to test the effect of drugs on the heart without using human or animal trials.

The breakthrough is the work of Dr Helen Maddock an expert in cardiovascular physiology and pharmacology from the University's Centre for Applied Biological and Exercise Sciences and could lead to the lives of hundreds of future patients being saved and the quality of their treatments improved.

Adverse effects of drugs on the cardiovascular system are a major cause of many medical treatments failing, but heart-related side-effects can often only be detected once a drug is being used on patients in clinical trials by which time it is too late.

Dr Maddock's 'in vitro' technique which means 'in glass' in reference to it taking place in a laboratory environment rather than in a living organism uses a specimen of human heart tissue attached to a rig allowing the muscle to be lengthened and shortened whilst being stimulated by an electrical impulse, mimicking the biomechanical performance of cardiac muscle.

Trial drugs can then be added to the tissue to determine whether or not they have an adverse effect on the force of contraction of the muscle (and therefore of the heart), a test that could only previously be performed 'in vivo' i.e. on living animals often with inconclusive results.

This 'simulated' cardiovascular system known as a work-loop assay provides the most realistic model of heart muscle dynamics in the world to date, and opens up unprecedented possibilities for identifying negative effects of drugs early and inexpensively potentially saving lives and speeding up the development of successful drug treatments.

Dr Maddock has formed a spin-out company InoCardia Ltd from Coventry University to begin implementing her groundbreaking technique in the pharma industry, and it has already received a quarter of a million pound investment from Warwickshire-based technology investment firm Mercia Fund Management.

Dr Maddock, who spent almost ten years developing the technique, said:

"I'm delighted that our research is at a stage where we can confidently say the work-loop assay we've created is the world's only clinically relevant in vitro human model of cardiac contractility. It has the potential to shave years off the development of successful drugs for a range of treatments.

"Both the pharma industry and regulators recognise that existing methods of assessing the contractility of the heart are fraught with problems, so we're incredibly excited to be able to introduce a new way to accurately determine the safety of drugs in respect of the heart without the need to test on humans or animals."

Mark Payton, managing director of Mercia Fund Management, added:

"InoCardia benefits from a proprietary approach following many years of investigation by Helen and her team, and offers the potential for early screening of compounds in development without the initial need for extensive animal trials. Through a markedly accelerated drug development process, this will decrease timelines to drug development, and as a consequence greatly reduce the cost of new drug development. The end beneficiary will, of course, be patients receiving novel treatments sooner."

Dr Maddock and InoCardia Ltd are already in discussions with a multinational biopharmaceutical company with a view to applying the assay in industry.


'/>"/>

Contact: Alex Roache
alex.roache@coventry.ac.uk
44-024-776-55050
Coventry University
Source:Eurekalert  

Related biology news :

1. New technique maps lifes effects on our DNA
2. Innovative technique may transform the hunt for new antibiotics and cancer therapies
3. Grass-in-the-ear technique sets new trend in chimp etiquette
4. Research team pursues techniques to improve elusive stem cell therapy
5. Big data technique improves monitoring of kidney transplant patients
6. New digital fabrication technique creates interlocking 3D-printed ceramic PolyBricks
7. Criminal profiling technique targets killer diseases
8. Developing an improved liposuction technique that melts fat
9. New technique to prevent anal sphincter lesions due to episiotomy during child delivery
10. Novel ORNL technique enables air-stable water droplet networks
11. Study validates air sampling techniques to fight bioterrorism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New technique uses 'simulated' human heart to screen drugs
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology: